15:52
+24 C°
Traffic jam:   6
$
77.5104
92.0669

Companies

Description

BioNTech is a German biotechnology company dedicated to the development and manufacture of active immunotherapies for a patient-specific approach to the treatment of serious diseases.

It develops pharmaceutical candidates based on messenger RNA (mRNA) for use as individualized cancer immunotherapies, as vaccines against infectious diseases and as protein replacement therapies for rare diseases, and also engineered cell therapy, novel antibodies and small molecule immunomodulators as treatment options for cancer. The company developed an mRNA-based human therapeutic for intravenous administration to bring individualized mRNA-based cancer immunotherapy to clinical trials and to establish its own manufacturing process.

In 2020, the company's lead vaccine candidate for preventing COVID-19 infections, BNT2b2, was in Phase III clinical trials in the United States.

History

BioNTech was founded in 2008 in Mainz, Germany, by German scientists Uğur Şahin, and Özlem Türeci, with the Austrian oncologist Christoph Huber.  It has been supported by a scientific advisory board under the direction of Rolf M. Zinkernagel.

In August 2018, the company announced that it had entered into a multi-year research and development (R&D) collaboration with the US company Pfizer Inc. to develop mRNA-based vaccines for prevention of influenza. Under the terms of the agreement, following BioNTech’s completion of a first in human clinical study, Pfizer would assume sole responsibility for further clinical development and commercialization of mRNA-based flu vaccines.

In September 2019, it signed an agreement with the Bill & Melinda Gates Foundation to develop HIV and tuberculosis programs to identify and develop preclinical vaccine and immunotherapy candidates for the prevention of HIV and tuberculosis infections and for the long-term antiretroviral therapy-free remission of HIV diseases.

In June 2020, BioNTech received €250 million from Singapore's Temasek Holdings and other investors through a private placement of mandatory convertible bonds.

Rating GlobalNY.biz

Take place
general
№24
general
Take place
area
№2
In rating
Healthcare
area

Company Persons

Chief Executive Officer of BioNTech
1 place

Discussion

NEW YORK COMPANIES


New York business portal GlobalNY.biz includes a huge directory of organizations operating in New York. Here you can easily find all the necessary information about the company. The organization card contains a full info page with a detailed description of the company's activities, logo, contact details and a link to the organization's official website. The reader can also immediately familiarize himself with the staff of the company, see the latest press releases and news block, and also see what line of the rating the company occupies. The rating of a member of the GlobalNY.biz business portal is calculated based on the number of mentions in the New York news and posted press releases containing information about the organization's activities and its achievements. You can also rise in the rating by publishing vacancies, as well as the number of registered persons. At the same time, company representatives can independently see how many times the company's card has been viewed on GlobalNY.biz, as well as promptly correct the information.
We pay special attention to the multifunctionality of the "Companies" section. For your convenience, there is a search box, as well as an industry heading.
New York Business Portal is always up-to-date database of New York enterprises!
Alena Potapova

Development Director